First filing for Chugai's ALK contender alectinib, in Japan
This article was originally published in Scrip
Roche's Japanese subsidiary Chugai has submitted the first approval application globally for alectinib (AF802/RG7853), seeking approval of the second-generation oral anaplastic lymphoma kinase (ALK) inhibitor in Japan for the treatment of non-small cell lung cancer (NSCLC).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.